InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Browse the full record of transactions filed by Brophy Michael Burkes, Chief Financial Officer. Director active across 1 companies, notably Natera, Inc.. Aggregated, 35 filings have been published. Total volume traded: €4.2m. The latest transaction was filed on 2 March 2022 (Attribution). Regulator: SEC (Form 4). All data is free.
Declarations35 total
2,292 shares
Common Stock
SEC:0001415889-22-007065:0·
1,077 shares
Common Stock
SEC:0001415889-22-006921:0·
1,144 shares
Common Stock
SEC:0001415889-22-004243:0·
2,291 shares
Common Stock
SEC:0001415889-22-003454:0·
1,078 shares
Common Stock
SEC:0001415889-22-003343:0·
3,021 shares
Common Stock
SEC:0001415889-22-002909:0·
07,353 shares0
Common Stock
SEC:0001415889-22-002615:0·
4,579 shares
Common Stock
SEC:0001415889-22-000758:0·
4,579 shares
Common Stock
SEC:0001415889-22-000758·
2,292 shares
Common Stock
SEC:0001415889-21-006280·
2,292 shares
Common Stock
SEC:0001415889-21-006280:0·
1,077 shares
Common Stock
SEC:0001415889-21-006232·
1,077 shares
Common Stock
SEC:0001415889-21-006232:0·
3,021 shares
Common Stock
SEC:0001415889-21-005853·
3,021 shares
Common Stock
SEC:0001415889-21-005853:0·
8,750 shares
Common Stook
SEC:0001415889-21-005762·
8,750 shares
Common Stook
SEC:0001415889-21-005762:0·
€2m22,178 shares@ €95.70840.0080% mcap95.9% of flow
Common Stock
SEC:0001415889-21-005181·
€2m22,178 shares@ €95.70840.0080% mcap48.0% of flow
Common Stock
SEC:0001415889-21-005181:0·
2,292 shares
Common Stock
SEC:0001415889-21-004609·
2,292 shares
Common Stock
SEC:0001415889-21-004609:0·
1,077 shares
Common Stock
SEC:0001415889-21-004551·
1,077 shares
Common Stock
SEC:0001415889-21-004551:0·
3,021 shares
Common Stock
SEC:0001415889-21-004374·
3,021 shares
Common Stock
SEC:0001415889-21-004374:0·
25 of 35 declarations
About Brophy Michael Burkes
Brophy Michael Burkes is the Chief Financial Officer of Natera, Inc., a publicly traded U.S. diagnostics and genetic testing company listed on NASDAQ. He joined Natera in 2015 and advanced through several leadership positions before being appointed CFO effective February 1, 2017. His internal progression included service as vice president of corporate development and investor relations, followed by senior vice president of finance and investor relations. That career path suggests a blend of financial management, strategic planning, and capital-markets experience developed directly within one of the company’s core leadership tracks. Before joining Natera, Brophy worked at Morgan Stanley as a vice president and executive director in the investment banking division, where he advised corporate clients in the life science tools and diagnostics sector. That background is especially relevant for a healthcare technology company because it typically involves exposure to financing strategy, corporate transactions, investor communications, and sector-specific valuation discipline. Public biographical material from Natera also notes a military leadership role earlier in his career: he led a multi-agency, 10-person team on a $1.4 billion contract to modernize 10 remote satellite tracking stations worldwide. This adds an operational and program-management dimension to his profile. Academically, Brophy holds a bachelor’s degree in economics from the United States Air Force Academy and an MBA from UCLA. Taken together, his experience reflects a finance executive with a strong foundation in investment banking, corporate development, and investor relations, alongside practical leadership in large-scale, complex programs. The public record reviewed for this profile does not clearly establish additional company leadership roles beyond Natera, so it is best to keep the description focused on his confirmed responsibilities, background, and expertise rather than speculate about other positions or decisions.
